Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences

Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying CCNE1 amplification to determine the effect of this amplification for future therapeutic development. We reviewed the medical records of patien...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 12; no. 1; pp. 8701 - 9
Main Authors Yao, Shuyang, Meric-Bernstam, Funda, Hong, David, Janku, Filip, Naing, Aung, Piha-Paul, Sarina Anne, Tsimberidou, Apostolia Maria, Karp, Daniel, Subbiah, Vivek, Yap, Timothy Anthony, Ahnert, Jordi Rodon, Pant, Shubham, Dumbrava, Ecaterina E Ileana, Wathoo, Chetna, Campbell, Erick, Yu, Lihou, Yamamura, Yuko, Fu, Siqing
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 24.05.2022
Nature Publishing Group
Nature Portfolio
Subjects
631/337
631/67
692/4028
Angiogenesis
Body mass index
Clinical Trials, Phase I as Topic
Cyclin E
Cyclin E - genetics
Gene Amplification
Humanities and Social Sciences
Humans
Medical records
Metastases
Middle Aged
multidisciplinary
Mutation
Neoplasms - genetics
Oncogene Proteins - genetics
p53 Protein
Patients
Retrospective Studies
Science
Science (multidisciplinary)
Solid tumors
Survival
Tumors
Online AccessGet full text
ISSN2045-2322
2045-2322
DOI10.1038/s41598-022-12669-5

Cover

Abstract Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying CCNE1 amplification to determine the effect of this amplification for future therapeutic development. We reviewed the medical records of patients with advanced solid tumors harboring CCNE1 amplification who were seen at the phase I clinic between September 1, 2012, and December 31, 2019. Among 79 patients with solid tumors harboring CCNE1 amplification, 56 (71%) received phase 1 clinical trial therapy, 39 (49%) had 3 or more concurrent genomic aberrances, and 52 (66%) had a concurrent TP53 mutation. The median overall survival (OS) after patients’ initial phase I visit was 8.9 months and after their initial metastasis diagnosis was 41.4 months. We identified four factors associated with poor risk: age < 45 years, body mass index ≥ 25 kg/m 2 , presence of the TP53 mutation, and elevated LDH > upper limit of normal. In patients treated with gene aberration-related therapy, anti-angiogenic therapy led to significantly longer OS after their initial phase I trial therapy than those who did not: 26 months versus 7.4 months, respectively (P = 0.04). This study provided preliminary evidence that CCNE1 amplification was associated with frequent TP53 mutation and aggressive clinical outcomes. Survival benefit was observed in patients who received antiangiogenic therapy and gene aberration-related treatment, supporting the future development of a personalized approach to combine gene aberration-related therapy with antiangiogenesis for the treatment of advanced malignancies harboring CCNE1 amplification.
AbstractList Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying CCNE1 amplification to determine the effect of this amplification for future therapeutic development. We reviewed the medical records of patients with advanced solid tumors harboring CCNE1 amplification who were seen at the phase I clinic between September 1, 2012, and December 31, 2019. Among 79 patients with solid tumors harboring CCNE1 amplification, 56 (71%) received phase 1 clinical trial therapy, 39 (49%) had 3 or more concurrent genomic aberrances, and 52 (66%) had a concurrent TP53 mutation. The median overall survival (OS) after patients’ initial phase I visit was 8.9 months and after their initial metastasis diagnosis was 41.4 months. We identified four factors associated with poor risk: age < 45 years, body mass index ≥ 25 kg/m 2 , presence of the TP53 mutation, and elevated LDH > upper limit of normal. In patients treated with gene aberration-related therapy, anti-angiogenic therapy led to significantly longer OS after their initial phase I trial therapy than those who did not: 26 months versus 7.4 months, respectively (P = 0.04). This study provided preliminary evidence that CCNE1 amplification was associated with frequent TP53 mutation and aggressive clinical outcomes. Survival benefit was observed in patients who received antiangiogenic therapy and gene aberration-related treatment, supporting the future development of a personalized approach to combine gene aberration-related therapy with antiangiogenesis for the treatment of advanced malignancies harboring CCNE1 amplification.
Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying CCNE1 amplification to determine the effect of this amplification for future therapeutic development. We reviewed the medical records of patients with advanced solid tumors harboring CCNE1 amplification who were seen at the phase I clinic between September 1, 2012, and December 31, 2019. Among 79 patients with solid tumors harboring CCNE1 amplification, 56 (71%) received phase 1 clinical trial therapy, 39 (49%) had 3 or more concurrent genomic aberrances, and 52 (66%) had a concurrent TP53 mutation. The median overall survival (OS) after patients' initial phase I visit was 8.9 months and after their initial metastasis diagnosis was 41.4 months. We identified four factors associated with poor risk: age < 45 years, body mass index ≥ 25 kg/m2, presence of the TP53 mutation, and elevated LDH > upper limit of normal. In patients treated with gene aberration-related therapy, anti-angiogenic therapy led to significantly longer OS after their initial phase I trial therapy than those who did not: 26 months versus 7.4 months, respectively (P = 0.04). This study provided preliminary evidence that CCNE1 amplification was associated with frequent TP53 mutation and aggressive clinical outcomes. Survival benefit was observed in patients who received antiangiogenic therapy and gene aberration-related treatment, supporting the future development of a personalized approach to combine gene aberration-related therapy with antiangiogenesis for the treatment of advanced malignancies harboring CCNE1 amplification.Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying CCNE1 amplification to determine the effect of this amplification for future therapeutic development. We reviewed the medical records of patients with advanced solid tumors harboring CCNE1 amplification who were seen at the phase I clinic between September 1, 2012, and December 31, 2019. Among 79 patients with solid tumors harboring CCNE1 amplification, 56 (71%) received phase 1 clinical trial therapy, 39 (49%) had 3 or more concurrent genomic aberrances, and 52 (66%) had a concurrent TP53 mutation. The median overall survival (OS) after patients' initial phase I visit was 8.9 months and after their initial metastasis diagnosis was 41.4 months. We identified four factors associated with poor risk: age < 45 years, body mass index ≥ 25 kg/m2, presence of the TP53 mutation, and elevated LDH > upper limit of normal. In patients treated with gene aberration-related therapy, anti-angiogenic therapy led to significantly longer OS after their initial phase I trial therapy than those who did not: 26 months versus 7.4 months, respectively (P = 0.04). This study provided preliminary evidence that CCNE1 amplification was associated with frequent TP53 mutation and aggressive clinical outcomes. Survival benefit was observed in patients who received antiangiogenic therapy and gene aberration-related treatment, supporting the future development of a personalized approach to combine gene aberration-related therapy with antiangiogenesis for the treatment of advanced malignancies harboring CCNE1 amplification.
Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying CCNE1 amplification to determine the effect of this amplification for future therapeutic development. We reviewed the medical records of patients with advanced solid tumors harboring CCNE1 amplification who were seen at the phase I clinic between September 1, 2012, and December 31, 2019. Among 79 patients with solid tumors harboring CCNE1 amplification, 56 (71%) received phase 1 clinical trial therapy, 39 (49%) had 3 or more concurrent genomic aberrances, and 52 (66%) had a concurrent TP53 mutation. The median overall survival (OS) after patients' initial phase I visit was 8.9 months and after their initial metastasis diagnosis was 41.4 months. We identified four factors associated with poor risk: age < 45 years, body mass index ≥ 25 kg/m , presence of the TP53 mutation, and elevated LDH > upper limit of normal. In patients treated with gene aberration-related therapy, anti-angiogenic therapy led to significantly longer OS after their initial phase I trial therapy than those who did not: 26 months versus 7.4 months, respectively (P = 0.04). This study provided preliminary evidence that CCNE1 amplification was associated with frequent TP53 mutation and aggressive clinical outcomes. Survival benefit was observed in patients who received antiangiogenic therapy and gene aberration-related treatment, supporting the future development of a personalized approach to combine gene aberration-related therapy with antiangiogenesis for the treatment of advanced malignancies harboring CCNE1 amplification.
Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying CCNE1 amplification to determine the effect of this amplification for future therapeutic development. We reviewed the medical records of patients with advanced solid tumors harboring CCNE1 amplification who were seen at the phase I clinic between September 1, 2012, and December 31, 2019. Among 79 patients with solid tumors harboring CCNE1 amplification, 56 (71%) received phase 1 clinical trial therapy, 39 (49%) had 3 or more concurrent genomic aberrances, and 52 (66%) had a concurrent TP53 mutation. The median overall survival (OS) after patients’ initial phase I visit was 8.9 months and after their initial metastasis diagnosis was 41.4 months. We identified four factors associated with poor risk: age < 45 years, body mass index ≥ 25 kg/m2, presence of the TP53 mutation, and elevated LDH > upper limit of normal. In patients treated with gene aberration-related therapy, anti-angiogenic therapy led to significantly longer OS after their initial phase I trial therapy than those who did not: 26 months versus 7.4 months, respectively (P = 0.04). This study provided preliminary evidence that CCNE1 amplification was associated with frequent TP53 mutation and aggressive clinical outcomes. Survival benefit was observed in patients who received antiangiogenic therapy and gene aberration-related treatment, supporting the future development of a personalized approach to combine gene aberration-related therapy with antiangiogenesis for the treatment of advanced malignancies harboring CCNE1 amplification.
Abstract Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying CCNE1 amplification to determine the effect of this amplification for future therapeutic development. We reviewed the medical records of patients with advanced solid tumors harboring CCNE1 amplification who were seen at the phase I clinic between September 1, 2012, and December 31, 2019. Among 79 patients with solid tumors harboring CCNE1 amplification, 56 (71%) received phase 1 clinical trial therapy, 39 (49%) had 3 or more concurrent genomic aberrances, and 52 (66%) had a concurrent TP53 mutation. The median overall survival (OS) after patients’ initial phase I visit was 8.9 months and after their initial metastasis diagnosis was 41.4 months. We identified four factors associated with poor risk: age < 45 years, body mass index ≥ 25 kg/m2, presence of the TP53 mutation, and elevated LDH > upper limit of normal. In patients treated with gene aberration-related therapy, anti-angiogenic therapy led to significantly longer OS after their initial phase I trial therapy than those who did not: 26 months versus 7.4 months, respectively (P = 0.04). This study provided preliminary evidence that CCNE1 amplification was associated with frequent TP53 mutation and aggressive clinical outcomes. Survival benefit was observed in patients who received antiangiogenic therapy and gene aberration-related treatment, supporting the future development of a personalized approach to combine gene aberration-related therapy with antiangiogenesis for the treatment of advanced malignancies harboring CCNE1 amplification.
ArticleNumber 8701
Author Karp, Daniel
Yu, Lihou
Hong, David
Dumbrava, Ecaterina E Ileana
Yap, Timothy Anthony
Ahnert, Jordi Rodon
Tsimberidou, Apostolia Maria
Campbell, Erick
Wathoo, Chetna
Pant, Shubham
Meric-Bernstam, Funda
Janku, Filip
Yao, Shuyang
Yamamura, Yuko
Subbiah, Vivek
Naing, Aung
Piha-Paul, Sarina Anne
Fu, Siqing
Author_xml – sequence: 1
  givenname: Shuyang
  surname: Yao
  fullname: Yao, Shuyang
  organization: Department of Thoracic Surgery, Xuanwu Hospital Capital Medical University
– sequence: 2
  givenname: Funda
  surname: Meric-Bernstam
  fullname: Meric-Bernstam, Funda
  organization: Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center
– sequence: 3
  givenname: David
  surname: Hong
  fullname: Hong, David
  organization: Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center
– sequence: 4
  givenname: Filip
  surname: Janku
  fullname: Janku, Filip
  organization: Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center
– sequence: 5
  givenname: Aung
  surname: Naing
  fullname: Naing, Aung
  organization: Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center
– sequence: 6
  givenname: Sarina Anne
  surname: Piha-Paul
  fullname: Piha-Paul, Sarina Anne
  organization: Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center
– sequence: 7
  givenname: Apostolia Maria
  surname: Tsimberidou
  fullname: Tsimberidou, Apostolia Maria
  organization: Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center
– sequence: 8
  givenname: Daniel
  surname: Karp
  fullname: Karp, Daniel
  organization: Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center
– sequence: 9
  givenname: Vivek
  surname: Subbiah
  fullname: Subbiah, Vivek
  organization: Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center
– sequence: 10
  givenname: Timothy Anthony
  surname: Yap
  fullname: Yap, Timothy Anthony
  organization: Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center
– sequence: 11
  givenname: Jordi Rodon
  surname: Ahnert
  fullname: Ahnert, Jordi Rodon
  organization: Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center
– sequence: 12
  givenname: Shubham
  surname: Pant
  fullname: Pant, Shubham
  organization: Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center
– sequence: 13
  givenname: Ecaterina E Ileana
  surname: Dumbrava
  fullname: Dumbrava, Ecaterina E Ileana
  organization: Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center
– sequence: 14
  givenname: Chetna
  surname: Wathoo
  fullname: Wathoo, Chetna
  organization: Institute of Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center
– sequence: 15
  givenname: Erick
  surname: Campbell
  fullname: Campbell, Erick
  organization: Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center
– sequence: 16
  givenname: Lihou
  surname: Yu
  fullname: Yu, Lihou
  organization: Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center
– sequence: 17
  givenname: Yuko
  surname: Yamamura
  fullname: Yamamura, Yuko
  organization: Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center
– sequence: 18
  givenname: Siqing
  surname: Fu
  fullname: Fu, Siqing
  email: siqingfu@mdanderson.org
  organization: Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35610322$$D View this record in MEDLINE/PubMed
BookMark eNp9kk1vEzEQhleoiJbSP8ABWeLCZcH22o7NAakKBSIVuMDZmnjHiauNvdgbPv49TtJC20N9sWW_7zMznnnaHMUUsWmeM_qa0U6_KYJJo1vKecu4UqaVj5oTToVsecf50a3zcXNWyhWtS3IjmHnSHHdSVQjnJ02eDyEGBwNxa8jgJsyhTMEVArEnaTu5tMFCkifjGgqSBXEQHWYywhQwToX8CtOazOdfLhiBzTgEX2lTSPEt-fyenMcec0mR4O-xkrFay7PmsYeh4Nn1ftp8_3Dxbf6pvfz6cTE_v2ydFHRqPcyMoABa8Y4ZxmYCuOuU7l2trDdsxj3zaKTwnHvBgKNkGpykaLzR3nenzeLA7RNc2TGHDeQ_NkGw-4uUVxZyLXVAC3LZaQUoeo-ihlpSEDOmVNfPTL1WlfXuwBq3yw32rlaeYbgDvfsSw9qu0k9rWEe50RXw6hqQ048tlsluQnE4DBAxbYvdtVBSzugu1st70qu0zbF-1U6lpdJKyqp6cTujf6nctLYK9EHgciolo7cuTPvO1ATDYBm1u0Gyh0GydZDsfpDsjs3vWW_oD5q6g6lUcVxh_p_2A66_elHaOw
CitedBy_id crossref_primary_10_1016_j_tvr_2024_200299
crossref_primary_10_3390_ijms232113206
crossref_primary_10_1016_j_bbadis_2024_167250
crossref_primary_10_3390_cancers17030335
crossref_primary_10_1096_fba_2023_00115
crossref_primary_10_1038_s41598_025_92757_4
crossref_primary_10_3389_fonc_2023_1227657
crossref_primary_10_1021_acs_jmedchem_4c01458
crossref_primary_10_1038_s41420_023_01413_1
crossref_primary_10_3390_cells13090786
crossref_primary_10_1016_j_ygeno_2024_110820
crossref_primary_10_1200_JCO_22_00830
crossref_primary_10_1016_j_ejmech_2025_117503
crossref_primary_10_1038_s41416_023_02508_3
Cites_doi 10.1038/nrc.2016.138
10.1016/j.lungcan.2014.09.005
10.1021/acs.jmedchem.8b01469
10.1016/j.ejca.2008.10.026
10.1200/JCO.18.00925
10.1016/j.ejca.2013.09.011
10.1038/modpathol.2010.60
10.1038/nrc2602
10.1038/s41598-020-58366-z
10.18632/oncotarget.25947
10.1093/annonc/mdv066
10.1038/bjc.2014.518
10.1158/1078-0432.CCR-11-2217
10.1056/NEJMoa052122
10.1128/MCB.00412-12
10.1038/bjc.2012.461
10.1016/j.cca.2011.12.020
10.1073/pnas.1807155115
10.18632/oncotarget.4600
10.1101/gad.14.1.34
10.1126/scisignal.2004088
10.1038/3957
10.1007/978-981-10-6955-0_16
10.1016/S0140-6736(10)61121-X
10.1158/1078-0432.CCR-13-1337
10.18632/oncotarget.16840
10.1038/modpathol.2016.160
10.3892/ijo.2015.3268
10.1186/s12885-019-5290-4
10.1186/1471-230X-14-78
10.1007/s00432-007-0270-5
10.1158/0008-5472.CAN-13-2247
10.1016/j.ygyno.2014.02.038
10.3390/diagnostics10050279
10.1093/annonc/mdu535
10.1158/1078-0432.CCR-17-3831
10.1002/cncr.25244
10.1158/1538-7445.AM2021-974
ContentType Journal Article
Copyright The Author(s) 2022
2022. The Author(s).
The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2022
– notice: 2022. The Author(s).
– notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.1038/s41598-022-12669-5
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Database
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Publicly Available Content Database

CrossRef
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 9
ExternalDocumentID oai_doaj_org_article_a5b386ae4dfe4117b0a471663d796ae6
PMC9130298
35610322
10_1038_s41598_022_12669_5
Genre Journal Article
Review
GrantInformation_xml – fundername: NIH/NCI Cancer Center Support Grant
  grantid: P30CA016672
– fundername: ;
  grantid: P30CA016672
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFPKN
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
7XB
8FK
AARCD
K9.
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c540t-fa7940aa8623191174a2c368dc204d9172f1fe954f22f41a2e518ac50e9f98ff3
IEDL.DBID 7X7
ISSN 2045-2322
IngestDate Wed Aug 27 01:29:26 EDT 2025
Thu Aug 21 14:03:56 EDT 2025
Fri Jul 11 05:35:53 EDT 2025
Wed Aug 13 06:12:06 EDT 2025
Mon Jul 21 06:02:38 EDT 2025
Thu Apr 24 22:59:35 EDT 2025
Tue Jul 01 04:16:30 EDT 2025
Fri Feb 21 02:39:29 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2022. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540t-fa7940aa8623191174a2c368dc204d9172f1fe954f22f41a2e518ac50e9f98ff3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
OpenAccessLink https://www.proquest.com/docview/2668568655?pq-origsite=%requestingapplication%
PMID 35610322
PQID 2668568655
PQPubID 2041939
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_a5b386ae4dfe4117b0a471663d796ae6
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9130298
proquest_miscellaneous_2669502106
proquest_journals_2668568655
pubmed_primary_35610322
crossref_citationtrail_10_1038_s41598_022_12669_5
crossref_primary_10_1038_s41598_022_12669_5
springer_journals_10_1038_s41598_022_12669_5
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-05-24
PublicationDateYYYYMMDD 2022-05-24
PublicationDate_xml – month: 05
  year: 2022
  text: 2022-05-24
  day: 24
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2022
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Odegaard, Vincent, Mortimer (CR20) 2018; 24
Singh, Patel, Routbort (CR18) 2014; 111
Wheler, Tsimberidou, Hong (CR41) 2012; 18
Davis, Tinker, Friedlander (CR17) 2014; 133
CR19
Ambs, Merriam, Ogunfusika (CR34) 1998; 4
Wang, Piha-Paul, Janku (CR38) 2017; 8
Otto, Sicinski (CR1) 2017; 17
Zhao, Yost, Hutchinson (CR15) 2019; 19
Montero, Abreu, Tonino (CR32) 2008; 134
Liu, Guan, Zhang (CR35) 2014; 7
Wang, Wang, Piha-Paul (CR39) 2018; 9
Stinchcombe, Johnson (CR24) 2014; 86
Joshi, Bhanot, Borresen-Dale, Kristensen (CR31) 2012; 107
Grant, Cook (CR26) 2017; 1042
Yang, Fang, Chen (CR28) 2015; 6
Zhou, Bandla, Ye (CR12) 2014; 14
Gorski, Ueland, Kolesar (CR8) 2020; 10
Sehdev, Kurman, Kuhn, Shih (CR5) 2010; 23
Malumbres, Barbacid (CR2) 2009; 9
Tadesse, Caldon, Tilley, Wang (CR27) 2019; 62
Nakayama, Nakayama, Shamima (CR16) 2010; 116
Wang, Janku, Piha-Paul (CR37) 2020; 10
Ayhan, Kuhn, Wu (CR14) 2017; 30
Fu, Hou, Naing (CR36) 2015; 26
Romond, Perez, Bryant (CR22) 2005; 353
Beck, Nahse-Kumpf, Larsen (CR30) 2012; 32
Bang, Van Cutsem, Feyereislova (CR23) 2010; 376
Turner, Liu, Zhu (CR6) 2019; 37
Santala, Talvensaari-Mattila, Soini, Santala (CR10) 2015; 35
CR40
Huang, Wang, Chen (CR11) 2012; 413
Ravi, Mookerjee, Bhujwalla (CR33) 2000; 14
Pils, Bachmayr-Heyda, Auer (CR3) 2014; 50
Sonntag, Giebeler, Nevzorova (CR25) 2018; 115
Karst, Jones, Vena (CR4) 2014; 74
Alsina, Landolfi, Aura (CR9) 2015; 26
Nakayama, Rahman, Rahman (CR13) 2016; 48
Gao, Aksoy, Dogrusoz (CR7) 2013; 6
Eisenhauer, Therasse, Bogaerts (CR21) 2009; 45
Etemadmoghadam, Au-Yeung, Wall (CR29) 2013; 19
Z Zhou (12669_CR12) 2014; 14
X Liu (12669_CR35) 2014; 7
S Ambs (12669_CR34) 1998; 4
H Beck (12669_CR30) 2012; 32
12669_CR40
Y Wang (12669_CR37) 2020; 10
L Yang (12669_CR28) 2015; 6
E Montero (12669_CR32) 2008; 134
M Alsina (12669_CR9) 2015; 26
R Ravi (12669_CR33) 2000; 14
JW Gorski (12669_CR8) 2020; 10
TE Stinchcombe (12669_CR24) 2014; 86
J Gao (12669_CR7) 2013; 6
RR Singh (12669_CR18) 2014; 111
AS Sehdev (12669_CR5) 2010; 23
LN Huang (12669_CR11) 2012; 413
T Otto (12669_CR1) 2017; 17
12669_CR19
Z Wang (12669_CR38) 2017; 8
S Fu (12669_CR36) 2015; 26
EA Eisenhauer (12669_CR21) 2009; 45
R Sonntag (12669_CR25) 2018; 115
AM Karst (12669_CR4) 2014; 74
S Santala (12669_CR10) 2015; 35
Y Wang (12669_CR39) 2018; 9
NC Turner (12669_CR6) 2019; 37
S Tadesse (12669_CR27) 2019; 62
A Davis (12669_CR17) 2014; 133
D Pils (12669_CR3) 2014; 50
A Ayhan (12669_CR14) 2017; 30
ZM Zhao (12669_CR15) 2019; 19
D Etemadmoghadam (12669_CR29) 2013; 19
M Malumbres (12669_CR2) 2009; 9
YJ Bang (12669_CR23) 2010; 376
JI Odegaard (12669_CR20) 2018; 24
K Nakayama (12669_CR13) 2016; 48
EH Romond (12669_CR22) 2005; 353
J Wheler (12669_CR41) 2012; 18
GD Grant (12669_CR26) 2017; 1042
H Joshi (12669_CR31) 2012; 107
N Nakayama (12669_CR16) 2010; 116
References_xml – volume: 17
  start-page: 93
  year: 2017
  end-page: 115
  ident: CR1
  article-title: Cell cycle proteins as promising targets in cancer therapy
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc.2016.138
– volume: 86
  start-page: 121
  year: 2014
  end-page: 125
  ident: CR24
  article-title: MEK inhibition in non-small cell lung cancer
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2014.09.005
– volume: 62
  start-page: 4233
  year: 2019
  end-page: 4251
  ident: CR27
  article-title: Cyclin-dependent kinase 2 inhibitors in cancer therapy: An update
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.8b01469
– volume: 45
  start-page: 228
  year: 2009
  end-page: 247
  ident: CR21
  article-title: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2008.10.026
– volume: 37
  start-page: 1169
  year: 2019
  end-page: 1178
  ident: CR6
  article-title: Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.18.00925
– volume: 50
  start-page: 99
  year: 2014
  end-page: 110
  ident: CR3
  article-title: Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients—A study of the OVCAD consortium
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2013.09.011
– volume: 23
  start-page: 844
  year: 2010
  end-page: 855
  ident: CR5
  article-title: Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase
  publication-title: Mod. Pathol.
  doi: 10.1038/modpathol.2010.60
– volume: 9
  start-page: 153
  year: 2009
  end-page: 166
  ident: CR2
  article-title: Cell cycle, CDKs and cancer: A changing paradigm
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc2602
– volume: 10
  start-page: 3080
  year: 2020
  ident: CR37
  article-title: Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-020-58366-z
– volume: 9
  start-page: 33258
  year: 2018
  end-page: 33270
  ident: CR39
  article-title: Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.25947
– volume: 26
  start-page: 1012
  year: 2015
  end-page: 1018
  ident: CR36
  article-title: Phase I study of pazopanib and vorinostat: A therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdv066
– volume: 111
  start-page: 2014
  year: 2014
  end-page: 2023
  ident: CR18
  article-title: Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2014.518
– volume: 18
  start-page: 2922
  year: 2012
  end-page: 2929
  ident: CR41
  article-title: Survival of 1,181 patients in a phase I clinic: The MD Anderson Clinical Center for targeted therapy experience
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-11-2217
– volume: 353
  start-page: 1673
  year: 2005
  end-page: 1684
  ident: CR22
  article-title: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa052122
– volume: 32
  start-page: 4226
  year: 2012
  end-page: 4236
  ident: CR30
  article-title: Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.00412-12
– volume: 107
  start-page: 1722
  year: 2012
  end-page: 1728
  ident: CR31
  article-title: Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2012.461
– volume: 413
  start-page: 663
  year: 2012
  end-page: 668
  ident: CR11
  article-title: Meta-analysis for cyclin E in lung cancer survival
  publication-title: Clin. Chim. Acta
  doi: 10.1016/j.cca.2011.12.020
– volume: 115
  start-page: 9282
  year: 2018
  end-page: 9287
  ident: CR25
  article-title: Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma
  publication-title: Proc. Natl. Acad. Sci. U.S.A.
  doi: 10.1073/pnas.1807155115
– volume: 6
  start-page: 20801
  year: 2015
  end-page: 20812
  ident: CR28
  article-title: Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.4600
– volume: 14
  start-page: 34
  year: 2000
  end-page: 44
  ident: CR33
  article-title: Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha
  publication-title: Genes Dev.
  doi: 10.1101/gad.14.1.34
– volume: 6
  start-page: pl1
  year: 2013
  ident: CR7
  article-title: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal
  publication-title: Sci. Signal.
  doi: 10.1126/scisignal.2004088
– ident: CR40
– volume: 4
  start-page: 1371
  year: 1998
  end-page: 1376
  ident: CR34
  article-title: p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells
  publication-title: Nat. Med.
  doi: 10.1038/3957
– volume: 1042
  start-page: 335
  year: 2017
  end-page: 369
  ident: CR26
  article-title: The temporal regulation of S phase proteins during G1
  publication-title: Adv. Exp. Med. Biol.
  doi: 10.1007/978-981-10-6955-0_16
– volume: 376
  start-page: 687
  year: 2010
  end-page: 697
  ident: CR23
  article-title: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)61121-X
– volume: 19
  start-page: 5960
  year: 2013
  end-page: 5971
  ident: CR29
  article-title: Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-13-1337
– ident: CR19
– volume: 8
  start-page: 33796
  year: 2017
  end-page: 33806
  ident: CR38
  article-title: Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.16840
– volume: 30
  start-page: 297
  year: 2017
  end-page: 303
  ident: CR14
  article-title: CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis
  publication-title: Mod. Pathol.
  doi: 10.1038/modpathol.2016.160
– volume: 7
  start-page: 3202
  year: 2014
  end-page: 3212
  ident: CR35
  article-title: Predictors of recurrence in breast cancer subtypes with negative lymph node in a Chinese population
  publication-title: Int. J. Clin. Exp. Pathol.
– volume: 35
  start-page: 3393
  year: 2015
  end-page: 3397
  ident: CR10
  article-title: Cyclin E expression correlates with cancer-specific survival in endometrial endometrioid adenocarcinoma
  publication-title: Anticancer Res.
– volume: 48
  start-page: 506
  year: 2016
  end-page: 516
  ident: CR13
  article-title: CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas
  publication-title: Int. J. Oncol.
  doi: 10.3892/ijo.2015.3268
– volume: 19
  start-page: 96
  year: 2019
  ident: CR15
  article-title: CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer
  publication-title: BMC Cancer
  doi: 10.1186/s12885-019-5290-4
– volume: 14
  start-page: 78
  year: 2014
  ident: CR12
  article-title: Cyclin E involved in early stage carcinogenesis of esophageal adenocarcinoma by SNP DNA microarray and immunohistochemical studies
  publication-title: BMC Gastroenterol.
  doi: 10.1186/1471-230X-14-78
– volume: 134
  start-page: 193
  year: 2008
  end-page: 201
  ident: CR32
  article-title: Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas
  publication-title: J. Cancer Res. Clin. Oncol.
  doi: 10.1007/s00432-007-0270-5
– volume: 74
  start-page: 1141
  year: 2014
  end-page: 1152
  ident: CR4
  article-title: Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-13-2247
– volume: 133
  start-page: 624
  year: 2014
  end-page: 631
  ident: CR17
  article-title: "Platinum resistant" ovarian cancer: What is it, who to treat and how to measure benefit?
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2014.02.038
– volume: 10
  start-page: 279
  year: 2020
  ident: CR8
  article-title: CCNE1 amplification as a predictive biomarker of chemotherapy resistance in epithelial ovarian cancer
  publication-title: Diagnostics (Basel)
  doi: 10.3390/diagnostics10050279
– volume: 26
  start-page: 438
  year: 2015
  end-page: 439
  ident: CR9
  article-title: Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdu535
– volume: 24
  start-page: 3539
  year: 2018
  end-page: 3549
  ident: CR20
  article-title: Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-17-3831
– volume: 116
  start-page: 2621
  year: 2010
  end-page: 2634
  ident: CR16
  article-title: Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer
  publication-title: Cancer
  doi: 10.1002/cncr.25244
– volume: 19
  start-page: 96
  year: 2019
  ident: 12669_CR15
  publication-title: BMC Cancer
  doi: 10.1186/s12885-019-5290-4
– volume: 1042
  start-page: 335
  year: 2017
  ident: 12669_CR26
  publication-title: Adv. Exp. Med. Biol.
  doi: 10.1007/978-981-10-6955-0_16
– volume: 32
  start-page: 4226
  year: 2012
  ident: 12669_CR30
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.00412-12
– ident: 12669_CR40
  doi: 10.1158/1538-7445.AM2021-974
– volume: 24
  start-page: 3539
  year: 2018
  ident: 12669_CR20
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-17-3831
– volume: 107
  start-page: 1722
  year: 2012
  ident: 12669_CR31
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2012.461
– ident: 12669_CR19
– volume: 115
  start-page: 9282
  year: 2018
  ident: 12669_CR25
  publication-title: Proc. Natl. Acad. Sci. U.S.A.
  doi: 10.1073/pnas.1807155115
– volume: 86
  start-page: 121
  year: 2014
  ident: 12669_CR24
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2014.09.005
– volume: 23
  start-page: 844
  year: 2010
  ident: 12669_CR5
  publication-title: Mod. Pathol.
  doi: 10.1038/modpathol.2010.60
– volume: 26
  start-page: 1012
  year: 2015
  ident: 12669_CR36
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdv066
– volume: 48
  start-page: 506
  year: 2016
  ident: 12669_CR13
  publication-title: Int. J. Oncol.
  doi: 10.3892/ijo.2015.3268
– volume: 133
  start-page: 624
  year: 2014
  ident: 12669_CR17
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2014.02.038
– volume: 134
  start-page: 193
  year: 2008
  ident: 12669_CR32
  publication-title: J. Cancer Res. Clin. Oncol.
  doi: 10.1007/s00432-007-0270-5
– volume: 74
  start-page: 1141
  year: 2014
  ident: 12669_CR4
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-13-2247
– volume: 37
  start-page: 1169
  year: 2019
  ident: 12669_CR6
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.18.00925
– volume: 111
  start-page: 2014
  year: 2014
  ident: 12669_CR18
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2014.518
– volume: 17
  start-page: 93
  year: 2017
  ident: 12669_CR1
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc.2016.138
– volume: 116
  start-page: 2621
  year: 2010
  ident: 12669_CR16
  publication-title: Cancer
  doi: 10.1002/cncr.25244
– volume: 10
  start-page: 279
  year: 2020
  ident: 12669_CR8
  publication-title: Diagnostics (Basel)
  doi: 10.3390/diagnostics10050279
– volume: 50
  start-page: 99
  year: 2014
  ident: 12669_CR3
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2013.09.011
– volume: 19
  start-page: 5960
  year: 2013
  ident: 12669_CR29
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-13-1337
– volume: 6
  start-page: pl1
  year: 2013
  ident: 12669_CR7
  publication-title: Sci. Signal.
  doi: 10.1126/scisignal.2004088
– volume: 10
  start-page: 3080
  year: 2020
  ident: 12669_CR37
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-020-58366-z
– volume: 376
  start-page: 687
  year: 2010
  ident: 12669_CR23
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)61121-X
– volume: 18
  start-page: 2922
  year: 2012
  ident: 12669_CR41
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-11-2217
– volume: 6
  start-page: 20801
  year: 2015
  ident: 12669_CR28
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.4600
– volume: 9
  start-page: 33258
  year: 2018
  ident: 12669_CR39
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.25947
– volume: 30
  start-page: 297
  year: 2017
  ident: 12669_CR14
  publication-title: Mod. Pathol.
  doi: 10.1038/modpathol.2016.160
– volume: 14
  start-page: 34
  year: 2000
  ident: 12669_CR33
  publication-title: Genes Dev.
  doi: 10.1101/gad.14.1.34
– volume: 7
  start-page: 3202
  year: 2014
  ident: 12669_CR35
  publication-title: Int. J. Clin. Exp. Pathol.
– volume: 9
  start-page: 153
  year: 2009
  ident: 12669_CR2
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc2602
– volume: 45
  start-page: 228
  year: 2009
  ident: 12669_CR21
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2008.10.026
– volume: 4
  start-page: 1371
  year: 1998
  ident: 12669_CR34
  publication-title: Nat. Med.
  doi: 10.1038/3957
– volume: 8
  start-page: 33796
  year: 2017
  ident: 12669_CR38
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.16840
– volume: 26
  start-page: 438
  year: 2015
  ident: 12669_CR9
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdu535
– volume: 35
  start-page: 3393
  year: 2015
  ident: 12669_CR10
  publication-title: Anticancer Res.
– volume: 353
  start-page: 1673
  year: 2005
  ident: 12669_CR22
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa052122
– volume: 62
  start-page: 4233
  year: 2019
  ident: 12669_CR27
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.8b01469
– volume: 14
  start-page: 78
  year: 2014
  ident: 12669_CR12
  publication-title: BMC Gastroenterol.
  doi: 10.1186/1471-230X-14-78
– volume: 413
  start-page: 663
  year: 2012
  ident: 12669_CR11
  publication-title: Clin. Chim. Acta
  doi: 10.1016/j.cca.2011.12.020
SSID ssj0000529419
Score 2.4410217
SecondaryResourceType review_article
Snippet Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying...
Abstract Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 8701
SubjectTerms 631/337
631/67
692/4028
Angiogenesis
Body mass index
Clinical Trials, Phase I as Topic
Cyclin E
Cyclin E - genetics
Gene Amplification
Humanities and Social Sciences
Humans
Medical records
Metastases
Middle Aged
multidisciplinary
Mutation
Neoplasms - genetics
Oncogene Proteins - genetics
p53 Protein
Patients
Retrospective Studies
Science
Science (multidisciplinary)
Solid tumors
Survival
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJSQuiDcpBRmJG0S1HduxuZWlVUFqT1TqzZo4topUJdVm98C_Z-xkQ8PzwtV2rNE8POOM5xtC3rS-9V7XvmS6CaWsoiqt0U2pjdfK20ZolQqFz8716YX8fKkub7X6Sm_CRnjgkXGHoJrKaAiyjUFyXjcM8DxFP9nWFocz2Db6vFuXqRHVW1jJ7VQlwypzOKCnStVkIvXy0NqWauGJMmD_76LMXx9L_pQxzY7o5AG5P0WQ9Gik_CG5E7pH5O7YU_LbY7KekD6vqV9iMVPoWtpvN6hiYaB9pDdX6MHoJ-qT4Nd0QlgdaPo1S1er82NOIb03j9Nvvff07CM9ysUwfUfDjJE8PCEXJ8dfVqfl1Fih9BigbcoIaIUMAG8zaIHIVAnCV9q0XjDZ4gVORB6DVTIKESUHERQ34BULNloTY_WU7HV9F54T2rAGuK2BtaqWppFGRVu1EAWAtxBCQfiOyc5PqOOp-cW1y9nvyrhRMA4F47JgnCrI2_mbmxFz46-rPyTZzSsTXnYeQC1ykxa5f2lRQQ52kneTEQ8O9zdKp8rdgryep9H8Uk4FutBv8xqr0r0Zt3g2KspMSZViUzwwC1IvVGhB6nKm-3qVIb5tyidbU5B3O2X7QdafWbH_P1jxgtwTyUqYKoU8IHub9Ta8xMBr07zKNvYdxAspaA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9QwDI_GEBIviG8KAwWJNyi0aZImSAiNY9NAuj1x0t6iNE0Y0qkd7Z20_fdz0rSocOy1-VAS27Udxz8j9KY2tTG8NGnGK5vSwrFUCl6lXBjOjKwIZz5ReHnKT1b0-xk720NjuaN4gP1O187Xk1p16_eXv68-g8B_GlLGxYcelJBPFCO-TAfnMmW30G3QTKUv5bCM5v6A9U0kzWXMndk9dKafAoz_Ltvz3yeUf8VRg3o6vo_uRbsSHw6M8ADt2eYhujNUmrx6hLqI_7nGZo7QjHVT43a7AcazPW4dvjgHvYa_YePZocMRd7XH_sIWLxanRznW_hW6i5d9H_HyKz4MKTJtg-2EnNw_Rqvjox-LkzSWW0gNmG2b1GmQzUxr8HFALnNwVTQxBRe1IRmtwa0jLndWMuoIcTTXxLJcaMMyK50UzhVP0H7TNvYZwlVW6VyWOqtZSUVFBXOyqLUjWhuprU1QPh6yMhGL3JfEWKsQEy-EGgijgDAqEEaxBL2dxlwMSBw39v7iaTf19Cja4UPb_VRRKJVmVSG4trR2lsKGq0yDrgYbrC4lfOYJOhgpr0bOVDC_YNzn8ybo9dQMQukjLbqx7Tb0kcx70zDF04FRppUU3mKF32iCyhkLzZY6b2l-nQfgb-mjzFIk6N3IbH-W9f-jeH7zLl6gu8Tzf8ZSQg_Q_qbb2pdgaG2qV0F6rgG0ViQR
  priority: 102
  providerName: Scholars Portal
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3Lb9YwDLfGEBIXxJvCQEHiBhVtmqQJt1E2DaTtxKTdoiRNGNLUTl-_78B_j5M-UGEgcc1LSWzHTmz_AvCmda1zonZ5IazPWRV4rqSwuZBOcKcsFTwmCp-eiZNz9uWCX-wBnXNhUtB-grRMx_QcHfZ-QEUTk8Fo_IpDCJXzW3A7QrfHML5GNMu7SvRcsVJN-TFFJW_outJBCar_JvvyzzDJ33ylSQUd34d7k-1IDsfZPoA93z2EO-Nvkj8ewWbC-Lwibo3CTEzXkn63xaX6gfSBXF-i7iKfiYsk35AJW3Ug8VGWNM3ZUUlMjDQP04PeB3L6iRymNJi-I35BRx4ew_nx0dfmJJ--VMgdmmbbPBiUv8IYvMeg7JV4HTHUVUK2jhasxasbDWXwirNAaWCloZ6X0jheeBWUDKF6Avtd3_lnQGxhTalqU7S8ZtIyyYOqWhOoMU4Z7zMo503WbsIbj99eXOnk966kHgmjkTA6EUbzDN4ufa5HtI1_tv4Yabe0jEjZqaDffNMT52jDbSWF8awNnuGCbWFQH6Od1dYKi0UGBzPl9SS-g8bxJRcxZzeD10s1Cl70ppjO97vURvF4Y8Yhno6MssykilYpHpUZ1CsWWk11XdN9v0zg3ip6kpXM4N3MbL-m9feteP5_zV_AXRrloeA5ZQewv93s_Es0rrb2VZKmn8pLHqg
  priority: 102
  providerName: Springer Nature
Title Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
URI https://link.springer.com/article/10.1038/s41598-022-12669-5
https://www.ncbi.nlm.nih.gov/pubmed/35610322
https://www.proquest.com/docview/2668568655
https://www.proquest.com/docview/2669502106
https://pubmed.ncbi.nlm.nih.gov/PMC9130298
https://doaj.org/article/a5b386ae4dfe4117b0a471663d796ae6
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgExIviG8CozISbxAtcWzH5gV1pdOo1AoBk_YWOY69IU1JadoH_nvuXDdT-dhLKzluZefufF--3xHytrGNtbK0aSZrl_LCi1QrWadSWSmsrpkUWCg8X8izcz67EBcx4NbHa5W7MzEc1E1nMUZ-DIpECYlllB-XP1PsGoXZ1dhC4y45ROgydL7Ki3KIsWAWi-c61spkhTruQV9hTRnDjh5S6lTs6aMA2_8vW_PvK5N_5E2DOjp9SB5EO5KOt4R_RO649jG5t-0s-esJWUW8z2tq9xGZqWkb2m3WsGnX087T5RXoMfqZWiT_ikac1Z5igJZOJotpTg3eOvcxuPeBzj_RcSiJ6VrqBqTk_ik5P51-n5ylsb1CasFMW6fegCxmxoBPA3KYg2timC2kaizLeANuHPO5d1pwz5jnuWFO5MpYkTnttfK-eEYO2q51Lwits9rkujRZI0quaq6E10VjPDPGauNcQvLdS65sxB7HFhjXVciBF6raEqYCwlSBMJVIyLvhN8st8sats0-QdsNMRM0OA93qsopCWBlRF0oaxxvvOGy4zgzoZrC5mlLDsEzI0Y7yVRTlvrphvIS8GR6DEGJmxbSu24Q5WqD3DH_xfMsow0oKtFDh2ExIucdCe0vdf9L-uApA3xqzylol5P2O2W6W9f9X8fL2Xbwi9xnyfyZSxo_IwXq1ca_BsFrXoyA9I3I4Hs--zeD7ZLr48hVGJ3IyCsEK-Jxz9Rt2qCbA
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrRBcEG8CBYwEJ4iaOLbXRkKo3W61S7srhFqpt-A4NkWqkrLZFeqf4jcyzqtaHr31GjuR4_nG89njmQF4nZvcGDE0YSQyG7LE8VBJkYVCGsGNyqjgPlB4NheTY_bphJ9swK8uFsZfq-zWxHqhzkvjz8i30ZBILnwY5cfzH6GvGuW9q10JjQYWB_biJ27Zqg_TPZTvG0r3x0ejSdhWFQgNspNl6DRCMNIaqTzCL0ZGrqlJhMwNjViOuxfqYmcVZ45Sx2JNLY-lNjyyyinpXILfvQGbLEGqMIDN3fH885f-VMf7zVis2uicKJHbFVpIH8VGfQ0RIVTI1yxgXSjgX-z270uaf3hqawO4fxfutMyV7DRQuwcbtrgPN5talhcPYNFmGD0jZj0HNNFFTsrVEqfZVqR05PwULSeZEuMBtyBtZteK-CNhMhrNxzHR_p67a48T35PZHtmpg3DKgtg-N3P1EI6vZeofwaAoC_sESBZlOlZDHeV8yGTGJHcqybWjWhulrQ0g7iY5NW22c1904yytve6JTBvBpCiYtBZMygN4279z3uT6uLL3rpdd39Pn6a4flItvaav2qeZZIoW2LHeW4Q9nkUY2gCwvHyp8LALY6iSftotHlV5CPYBXfTOqvffl6MKWq7qP4n6_jp943AClH0niOTEu1AEM1yC0NtT1luL7aZ1aXHk_tpIBvOvAdjms_0_F06v_4iXcmhzNDtPD6fzgGdymXhciHlK2BYPlYmWfI61bZi9aXSLw9brV9zej3F45
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKEYgL4k2ggJHgBNEmju3YSAiV3a66lK44UGlvruPYtFKVbDe7Qv1r_DrGeVXh0VuvtmM5nm8e9nhmEHqTm9wYnpow4pkNaeJYKAXPQi4MZ0ZmhDMfKHw45_tH9MuCLbbQry4Wxj-r7GRiLajz0vg78hEoEsG4D6McufZZxLfJ9NPyPPQVpLyntSun0UDkwF78hONb9XE2AVq_JWS69328H7YVBkIDlso6dBrgGGkNZj1AMQbrXBOTcJEbEtEcTjLExc5KRh0hjsaaWBYLbVhkpZPCuQTmvYFupgmoTeCldJH29zveg0Zj2cbpRIkYVaArfTwb8dVEOJchG-jCumTAv-zcv59r_uGzrVXh9B6629qweLcB3X20ZYsH6FZT1fLiIVq1uUbPsBlmg8a6yHG5WcOG2wqXDi9PQIfiGTYeeivc5nitsL8cxuPxfC_G2r94d-3F4gd8OMG7dThOWWDbZ2muHqGja9n4x2i7KAv7FOEsynQsUx3lLKUio4I5meTaEa2N1NYGKO42WZk277kvv3Gmav97IlRDGAWEUTVhFAvQu_6bZZP148rRnz3t-pE-Y3fdUK5-qFYAKM2yRHBtae4shR_OIg12Adh7eSqhmQdop6O8asVIpS5BH6DXfTcIAO_V0YUtN_UYyfzJHaZ40gClX0nirWMQ2QFKBxAaLHXYU5ye1EnGpfdoSxGg9x3YLpf1_614dvVfvEK3gWnV19n84Dm6QzwrRCwkdAdtr1cb-wLsu3X2smYkjI6vm3N_Ax1BYQk
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+characteristics+and+outcomes+of+phase+I+cancer+patients+with+CCNE1+amplification%3A+MD+Anderson+experiences&rft.jtitle=Scientific+reports&rft.au=Yao+Shuyang&rft.au=Meric-Bernstam+Funda&rft.au=Hong%2C+David&rft.au=Janku+Filip&rft.date=2022-05-24&rft.pub=Nature+Publishing+Group&rft.eissn=2045-2322&rft.volume=12&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-022-12669-5&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon